Bedrijfsoverzicht
Kymera Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to the discovery and development of small molecule therapeutics that selectively degrade disease-causing proteins by leveraging the body's intrinsic protein degradation mechanisms. The company operates within the Healthcare sector, specifically inside the Biotechnology industry, a classification that signifies its focus on early-stage research and development rather than mature commercialization of established drugs. This organization employs a workforce of 238 individuals and holds a market capitalization of $6.94B, with reported annual revenue of $39.21M over the trailing twelve months. The valuation of $6.94B represents a significant premium relative to the reported revenue of $39.21M, indicating that the market assigns high value to the company's intellectual property and pipeline potential rather than current cash generation. This disparity between market cap and revenue is typical for clinical-stage biotechnology firms where future drug approvals are expected to drive substantial growth, yet current financial performance remains constrained by heavy investment in research and development activities.
Financiële gezondheid
The company reported a revenue of $39.21M for the trailing twelve months, yet this figure is overshadowed by a net income of $-311,351,008 and an EBITDA of $-338,831,008. The substantial gap between the modest revenue of $39.21M and the significant net loss of $-311,351,008 reveals a cost structure dominated by high research and development expenditures typical of biotechnology companies in the clinical stage. Free cash flow stands at $-136,041,248, which indicates that the company is burning cash to fund its operations and development pipeline rather than generating liquidity from its business activities. Despite these negative cash flows, Kymera Therapeutics maintains a cash reserve of $848.28M, providing a substantial buffer against its current burn rate and operational expenses. The balance sheet shows a debt level of $82.25M, resulting in a debt-to-equity ratio of 5.21, which suggests a leveraged position where debt is a significant component of the capital structure. Gross margin is reported at 0.0%, operating margin at -3411.0%, and profit margin at 0.0%, reflecting the accounting treatment of R&D costs and the absence of profitable operations in the current fiscal period. The current ratio is an impressive 10.47, indicating that the company possesses more than ten times the liquid assets necessary to cover its short-term liabilities, which points to strong short-term liquidity despite the operating losses. Return on Equity is -25.8% and Return on Assets is -15.9%, metrics that reveal management is currently deploying capital to generate losses rather than positive returns, a common characteristic for firms prioritizing asset growth and pipeline advancement over immediate profitability.
Waarderingsbeoordeling
The trailing P/E ratio is listed as N/A due to the lack of net income, while the forward P/E is reported at -21.22, implying that the market expects earnings to remain negative or for the company to be valued on growth potential rather than current profitability. The price-to-book ratio stands at 4.38, indicating that the stock trades at a significant premium of over four times its book value, which reflects the market's high expectations for the value of the company's intangible assets and future drug approvals. The price-to-sales ratio is exceptionally high at 177.09, suggesting that the market values the company primarily on its projected future sales rather than its current revenue stream, while the EV/EBITDA of -18.23 further underscores that traditional earnings-based valuation metrics are not applicable at this stage of development. The 52-week trading range spans from a low of $24.23 to a high of $103.00, illustrating a wide volatility band where the current price point fluctuates significantly relative to these historical extremes. The beta value of 2.29 indicates that the stock price is highly sensitive to market movements, typically experiencing volatility more than twice as intense as the broader market index. These valuation metrics collectively paint a picture of a high-risk, high-reward investment profile where the price is disconnected from current cash flows and earnings, driven instead by speculative expectations regarding the success of its drug candidates like KT-621.
Growth & Income
Revenue growth year-over-year is -61.2%, while earnings growth is N/A due to the absence of positive net income in the prior periods. The negative revenue growth combined with N/A earnings growth implies that the company is still in a phase where scaling up operations or commercialization is not yet contributing to positive momentum, and earnings cannot be compared favorably to revenue as losses are expected to persist until later stages. As a non-dividend payer, Kymera Therapeutics does not distribute a dividend yield or maintain a payout ratio, as evidenced by the 0.0% figures, meaning the company retains all available capital to reinvest into research, development, and clinical trials rather than providing income to shareholders. This strategy aligns with the standard operating model for clinical-stage biotechnology firms that prioritize capital expenditure for pipeline advancement over shareholder distributions. The overall growth and income profile is characterized by significant negative revenue trends and a complete lack of income generation, with the company's value proposition resting entirely on the potential success of its future product launches rather than current financial performance or dividend distributions.